Company
Our mission is to cure kidney diseases by discovering, developing and licensing novel gene therapies.
There are more than 450 rare monogenic kidney diseases without a cure. In most cases, patients reach end-stage renal failure and require dialysis and a kidney transplant, which significantly affects their quality of life.
Ninevah Therapeutics (NTX) lead program is an AAV-based approach for podocyte-associated genetic disorders (NTX014).
NTX is building a discovery portfolio with other programs.
Ninevah Therapeutics was founded in Barcelona and currently based in the UK.
